Tuesday, April 03, 2012
Apr 3rd early release: United States Cancer Statistics Public Information Data - Cancer Statiistics (searchable by organ site/state/age....)
United States Cancer Statistics Public Information Data
CDC's Division of Cancer Prevention and Control is pleased to announce the early release of National Program of Cancer Registries (NPCR) cancer incidence data for the years 1999–2009 to facilitate cancer control planning. The data are available through CDC WONDER at http://wonder.cdc.gov/cancer.html.
The data from selected NPCR registries cover between 86% and 96% of the United States population, depending on the specific year of diagnosis. This release is part of the NPCR Data Release Plan and is based on the NPCR Cancer Surveillance System 2012 data submission.
CDC WONDER is an online query system that produces age-adjusted and crude rates in tabular, map, and chart formats. Variables include year of diagnosis, state, region or division of the United States, sex, race, ethnicity, age, primary site, and childhood cancer.
National Program of Cancer Registries (NPCR)
Division of Cancer Prevention and Control (DCPC)
Centers for Disease Control and Prevention (CDC)
abstract: Cancer among patients with diabetes, obesity and abnormal blood lipids: a population-based register study in Sweden.
Blogger's Note: see also posting regarding BRCA1/heart disease/doxorubicin research... (blog posting Apr 3 eg. as per below abnormal lipid levels/ovarian cancer)
~~~~~~~~~~~~~~~~
Cancer among patients with diabetes, obesity and abnormal blood lipids: a population-based register study in Sweden.
Abstract
OBJECTIVE:
To study how the incidence of cancer is related to diabetes, obesity or abnormal blood lipids.METHODS:
Diagnosis of diabetes, obesity or abnormal blood lipids was studied 0-10 years prior to the diagnosis of cancer in 19,756 cases of cancer and in 147,324 controls matched regarding age, sex and domicile.RESULTS:
Diabetes was significantly more common prior to diagnosis in patients with liver, pancreatic, colon and urinary tract/bladder cancer and in patients with breast cancer diagnosed with diabetes 0-4 years prior to the cancer diagnosis. A lower risk of diabetes was seen in patients with prostate carcinoma among individuals with diabetes diagnosed 5-10 years prior to the cancer diagnosis. The findings remained after adjusting for obesity and high blood lipids. Obesity was significantly more common in patients with endometrial, colon and kidney cancer and with breast cancer above the age of 60 years in those where obesity was diagnosed close to the diagnosis of cancer. High blood lipids were significantly more common in patients with ovarian cancer and less common in patients with breast cancer.CONCLUSIONS:
The study confirms some previous findings concerning comorbidity and cancer and highlights some new ones.abstract: Study: Vast Majority of C difficile Infections Occur in Medical Settings, April 4, 2012, Voelker 307 (13): 1356 — JAMA
Study: Vast Majority of C difficile Infections Occur in Medical Settings, April 4, 2012
Most Clostridium difficile infections, often assumed to be community acquired, actually occur in medical settings, according to recent data from the
Centers for Disease Control and Prevention (CDC).
In fact, 94% of the potentially fatal infections are in people who recently received care in facilities such as hospitals,
nursing homes, physicians' offices, and outpatient surgical centers. To stem the rising tide of C difficile infections, CDC officials say hospitals and other health care settings need greater adherence to infection control practices
and improved communication to notify each other whenever they transfer an infected patient.
“These infections are now a patient safety concern everywhere medical care is given,” said Clifford McDonald, MD, a CDC medical
epidemiologist and lead author of the study in the Morbidity and Mortality Weekly Report (http://tinyurl.com/7dh83hh). “About 25% of C difficile infections first show symptoms among patients in hospitals; 75% first show symptoms among patients in nursing …"
abstract: Rare Mutations in XRCC2 Increase the Risk of Breast Cancer.
Blogger's Note: see recent post for a null finding XRCC/Lynch Syndrome
Rare Mutations in XRCC2 Increase the Risk of Breast Cancer.:
Am J Hum Genet. 2012 Mar 28;
Abstract
An exome-sequencing study of families with multiple breast-cancer-affected individuals identified two families with XRCC2 mutations, one with a protein-truncating mutation and one with a probably deleterious missense mutation. We performed a population-based case-control mutation-screening study that identified six probably pathogenic coding variants in 1,308 cases with early-onset breast cancer and no variants in 1,120 controls (the severity grading was p<0.02). We also performed additional mutation screening in 689 multiple-case families. We identified ten breast-cancer-affected families with protein-truncating or probably deleterious rare missense variants in XRCC2. Our identification of XRCC2 as a breast cancer susceptibility gene thus increases the proportion of breast cancers that are associated with homologous recombination-DNA-repair dysfunction and Fanconi anemia and could therefore benefit from specific targeted treatments such as PARP (poly ADP ribose polymerase) inhibitors. This study demonstrates the power of massively parallel sequencing for discovering susceptibility genes for common, complex diseases.
Cancer Fact or Fiction: Separating Myths from Good Information -- BETHESDA, Md., April 3, 2012 /PRNewswire-USNewswire/ --
Cancer Fact or Fiction: Separating Myths from Good Information -- BETHESDA, Md., April 3, 2012 /PRNewswire-USNewswire/
Translations: Español
BETHESDA, Md., April 3, 2012 /PRNewswire-USNewswire/ -- To many, cancer remains one of the most frightening diagnoses in modern medicine. But much of this fear is a result of myths that have circulated for years in spite of the good information that is available. Indeed, many of cancer's mysteries have been solved, and a great deal of success has been achieved in curing patients and helping them live longer and better lives. Despite advances in cancer treatment and prognosis, many continue to believe in myths surrounding cancer. In particular, studies have shown that Hispanics are more likely than whites to maintain some erroneous beliefs about cancer.
It is important to separate fact from fiction. Some of the most common cancer myths not only cultivate false ideas and fears but also can interfere with how people think and behave when facing cancer in themselves or in a loved one. It is important that the health messengers within the family and community have the most accurate information about cancer. In many Hispanic families, that is often the woman running the household. It is good for these health messengers and the people who listen to them to at least be aware of some of the most common cancer myths so that misinformation doesn't stand in the way of getting counsel from a medical professional.
What Will Happen to Me If I Get Cancer?Myth––Cancer is a death sentence. The fact is that more than 12 million cancer survivors are living in the United States. Thanks to improved treatments and earlier diagnosis of some cancers, more than 3 of every 5 cancer patients are alive 5 years after their diagnosis. For children, the 5-year survival rate is 4 in 5.
Who Gets Cancer and WhyMyth––Cancer is contagious. You cannot catch cancer from someone who has it. What can spread among people are microorganisms (viruses and bacteria), and a few of these can cause cancer. Recent Hispanic immigrants may have a greater risk of some cancers caused by infectious agents if there was a higher prevalence of related infections in their country of origin.
Myth––If a parent or close family member had cancer, you will inherit it. Cancer develops when genes change in certain ways, but most of these changes occur during a person's lifetime and are not inherited. But some cancer-causing gene changes are inherited, so if a certain cancer seems to run in your family it is important to discuss this with a doctor.
Myth––People get cancer from . . . (just fill in the blank as to what you have heard). Scientists are continuously doing research to determine whether particular natural or manmade substances cause cancer. Research shows that the following are not likely to cause cancer: cell phones, microwaves, fluoridated water, hair dyes, deodorants, sugar, artificial sweeteners like saccharin and aspartame, and low-frequency magnetic fields produced by power lines and household electric appliances.
What You Can Do About It Myth––You have no control over your own cancer risk. Although scientists haven't figured out how to completely prevent cancer, there are things you can do to reduce your risk of certain cancers. For example:
- Not smoking or quitting smoking greatly reduces your risk of developing and dying from lung cancer.
- Maintaining a healthy weight and being physically active cuts your risk of several cancers.
- HPV vaccines prevent infection with the virus that causes most cervical cancers. And regular cervical cancer screening detects most cervical abnormalities so that they can be treated before they become cancer.
- Colorectal cancer screening reduces the risk of developing and dying from colorectal cancer.
- For women age 40 and older, getting regular mammograms reduces the chance of dying from breast cancer. (ongoing controversies ??)
These are only some of the false and misleading ideas that can confuse and mislead people about the progress being made in cancer prevention, detection, and treatment. You can learn more from NCI about cancer prevention and screening.
open access: BRCA1 is an essential regulator of heart function and survival following myocardial infarction (in research, references doxorubicin)
Blogger's Note: technical paper, in research (eg. mice, tissue samples)
~~~~~~~~~~~~~~~~~
BRCA1 is an essential regulator of heart function and survival following myocardial infarction
"BRCA1 mutation carriers, in addition to risk of breast and ovarian cancer, may be at a previously unrecognized risk of cardiac failure."
FDA identifies more bogus cancer drugs (Avastin - labeled as Altuzan) in U.S | Reuters
FDA identifies more bogus cancer drugs in U.S | Reuters
The fake versions of Swiss drugmaker Roche's widely used cancer drug Avastin are labeled as Altuzan, which is the brand name that Avastin is sold under in Turkey, and do not contain the drug's active ingredient, bevacizumab.
Clinical Outcome Prediction by MicroRNAs in Human Cancer: A Systematic Review
Blogger's Note: 2nd link JNCI
~~~~~~~~~~~~~~~~
Clinical Outcome Prediction by MicroRNAs in Human Cancer: A Systematic Review:
Background
MicroRNA (miR) expression may have prognostic value for many types of cancers. However, the miR literature comprises many small studies. We systematically reviewed and synthesized the evidence.
Methods
Using MEDLINE (last update December 2010), we identified English language studies that examined associations between miRs and cancer prognosis using tumor specimens for more than 10 patients during classifier development. We included studies that assessed a major clinical outcome (nodal disease, disease progression, response to therapy, metastasis, recurrence, or overall survival) in an agnostic fashion using either polymerase chain reaction or hybridized oligonucleotide microarrays.
Results
Forty-six articles presenting results on 43 studies pertaining to 20 different types of malignancy were eligible for inclusion in this review. The median study size was 65 patients (interquartile range [IQR] = 34–129), the median number of miRs assayed was 328 (IQR = 250–470), and overall survival or recurrence were the most commonly measured outcomes (30 and 19 studies, respectively). External validation was performed in 21 studies, 20 of which reported at least one nominally statistically significant result for a miR classifier. The median hazard ratio for poor outcome in externally validated studies was 2.52 (IQR = 2.26–5.40). For all classifier miRs in studies that evaluated overall survival across diverse malignancies, the miRs most frequently associated with poor outcome after accounting for differences in miR assessment due to platform type were let-7 (decreased expression in patients with cancer) and miR 21 (increased expression).
Conclusions
MiR classifiers show promising prognostic associations with major cancer outcomes and specific miRs are consistently identified across diverse studies and platforms. These types of classifiers require careful external validation in large groups of cancer patients that have adequate protection from bias.
press release: Researchers discover a DNA marker (microRNA-16) that indicates if ovarian cancer treatment will be successful
Researchers discover a DNA marker that indicates if ovarian cancer treatment will be successful
Public release date: 3-Apr-2012
Researchers discover a DNA marker that indicates if ovarian cancer treatment will be successful
CHICAGO, IL – Researchers and doctors at the North Shore-LIJ Health System and the Feinstein Institute for Medical Research have discovered that blood can help determine the best treatment plan for patients with ovarian cancer. More specifically, a genetic marker embedded in deoxyribonucleic acid (DNA), called microRNA, indicates if a patient with ovarian cancer has a benign or cancerous tumor, and that she will benefit from chemotherapy after surgery on the tumor. This data will be presented at the American Association for Cancer Research (AACR) Annual Meeting to be held from Saturday through Wednesday (March 31- April 4) in Chicago, IL.It is estimated that there will be 22,280 new cases and 15,500 deaths this year from ovarian cancer in the United States. Due to lack of adequate screening, the majority of patients with ovarian cancer are diagnosed at stage III (the second-to-last and most devastating stage of cancer), when 70 percent of these patients will die of their disease within 5 years.
"The discovery that microRNAs can help predict the best treatment plan for women with ovarian cancer, who are most likely at stage III of the disease, offers them enormous hope," noted Iuliana Shapira, MD, director of the Cancer Genetics Program at the North Shore-LIJ Health System's Monter Cancer Center. "We can now inform patients at stage III ovarian cancer, if they will have success with chemotherapy following surgery, similar to patients who are at stage 1 disease. This information gives them hope that their disease is curable despite being diagnosed at an 'advanced stage.' It also gives them the strength necessary to undergo chemotherapy, which is a very invasive and toxic therapy necessary to obtain the cure." (Blogger's Note: a 'forward' looking statement; see text in red highlighted below)
Several microRNAs have been found to have links with various types of cancer. The research conducted at the North Shore-LIJ Health System and the Feinstein Institute for Medical Research found that microRNA-195 increased 40 fold during chemotherapy and microRNA-16 increased 80 fold during chemotherapy. These changes may explain why some patients with ovarian cancer have side effects of chemotherapy, why others become cured of cancer as a result of chemotherapy, and why others need ongoing chemotherapy to continue living with the cancer.
"Understanding the changes in microRNA throughout chemotherapy treatment helps us better understand ovarian cancer and how best to treat patients who have this disease," said Annette Lee, PhD, associate investigator at the Feinstein Institute. "The genetic markers we identified allow patients to individualize their own therapy in order to have maximum benefit and minimal side effects. In addition, this knowledge will help researchers develop new treatments for patients with ovarian cancer."
Dr. Shapira adds that, "We applied for a government grant and hope to receive the funds needed to validate these markers allow result in women receiving therapies that are more personalized and match their genetic makeup."
open access: CLINICIAN'S CORNER - Management of Ovarian Cancer, April 4, 2012 — JAMA (clear cell/endometrioid)
Management of Ovarian Cancer, April 4, 2012, — JAMA
"Using the case of Ms W, we discuss the signs, symptoms, risk factors, and prognostic factors of epithelial ovarian cancer; review the evidence for surgical and postoperative medical management; and present the current recommendations for screening and follow-up......
"A 75-Year-Old Woman Who Has Completed Treatment".......
press release: Nearly half of cancer survivors died from conditions other than cancer
Blogger's Opinion: while it is true that general health (patient/family physician connection) should be included in patients' wellness plans, this press release, does an injustice to cancer survivors who have have suffered, albeit longterm cancer survivors, as a result of treatment-related side effects/complications of which they may very well die (eg. connecting the dots - doxil/heart disease; Avastin/hypertension/bowel/intestinal complications.......); connecting the dots means would the patients have suffered apparent non-cancer related deaths if they had not had cancer/treatments; obviously important to actually read the research paper to elicit the details but the press release in itself is lacking in that it does not acknowledge the full patient experience; often research tries to 'dissect' the patient experience into bits and pieces and parts which of course does not work, IMHO.
Feel free to disagree and comment.
~~~~~~~~~~~~~
Nearly half of cancer survivors died from conditions other than cancer
CHICAGO -- Although cancer recurrence may be the overriding fear for many survivors, nearly half of survivors from a recently presented study died from other conditions.
These results indicate survivors could potentially benefit from a more comprehensive, less cancer-focused approach to their health, according to lead researcher Yi Ning, M.D., Sc.D., assistant professor in the department of epidemiology and community health at Virginia Commonwealth University (VCU) and associate research member at VCU Massey Cancer Center in Richmond, Va. Ning presented the results at the AACR Annual Meeting 2012, held here March 31 - April 4.
"We realized that the mortality rates for some types of cancer, such as breast cancer, had declined," said Ning. "Cancer survivors live much longer than they did several decades ago. So with this large group of cancer survivors, we need to pay more attention to cancer survivors' overall health."
Ning and colleagues evaluated 1,807 cancer survivors who had participated in the National Health and Nutrition Examination Surveys (NHANES) study. The most common forms of cancer among the study group were breast, prostate, cervical, lung and colorectal.
When originally surveyed through NHANES, a large percentage of the study group suffered from conditions other than cancer, including cardiovascular conditions, hypertension and diabetes.
Researchers followed patients for more than 18 years. During the course of the study, 776 cancer survivors died. Fifty-one percent died from cancer and 49 percent died from other causes. Cardiovascular disease was the primary cause of noncancer deaths.
Researchers found that the longer patients survived after their initial cancer diagnosis, the more likely they were to die from another disease: 32.8 percent died from another condition within five years of diagnosis compared with 62.7 percent after 20 years.
With nearly half of cancer survivors dying from other causes, Ning said that physicians and patients must improve efforts to manage those risks.
"After the detection of cancer, clinicians and cancer survivors pay less attention to the prevention and treatment of other diseases and complications," said Ning. "We shouldn't neglect other aspects of health because we are focused on cancer and overlook other chronic conditions."
financial: Access Pharmaceuticals Investor Call Tomorrow, Wednesday April 4th at... -- DALLAS and NEW YORK, April 3, 2012 /PRNewswire/ --
Access Pharmaceuticals Investor Call Tomorrow, Wednesday April 4th at... -- DALLAS and NEW YORK, April 3, 2012 /PRNewswire/ --
"....Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac™, a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas......"
press release: Mayo Clinic study identifies optimal gene targets for new colon cancer test
Blogger's Note: see other posting today on non-invasive testing for those at average risk/including link to the clinical trial
Mayo Clinic study identifies optimal gene targets for new colon cancer test
ROCHESTER, Minn. -- A study presented today by Mayo Clinic researchers at the American Association for Cancer Research (AACR) Annual Meeting 2012 in Chicago identified two genes that are optimal targets to be analyzed in a new noninvasive test for colorectal cancer developed by Mayo Clinic, in collaboration with Exact Sciences Corporation. The test uses a small sample of a patient's stool to check for specific DNA changes, known as gene methylation, that occur as cancer develops. The test can quickly detect both early stage cancer and precancerous polyps.
Medscape: Bleeding Rates and Medical Costs of New Oral Anticoagulants (warfarin, dabigatran...)
Bleeding Rates and Medical Costs of New Oral Anticoagulants
April 2, 2012 (Chicago, Illinois) — Firsthand experience with the new oral anticoagulants, coupled with excitement over those yet to be widely in use, has inspired a range of studies examining real-world risk/benefits, as well as the potential costs of replacing warfarin with the new agents.
In a poster session at last week's American College of Cardiology 2012 Scientific Sessions, investigators presented two separate experiences with dabigatran from different US centers--showing very different results--while others presented new cost analyses comparing different oral agents with warfarin.
One US report of patients switched to dabigatran showed a much higher rate of major bleeding than in the RE-LY trial, but a lower rate of dyspepsia, while a second report showed a lower rate of both major and minor bleeding compared with RE-LY trial.
media: (U.S.) Higher-Spending Hospitals Have Fewer Deaths for Emergency Patients
Blogger's Note: a similar report from Canada was posted recently (eg. higher spending hospitals)
Higher-Spending Hospitals Have Fewer Deaths for Emergency Patients
bloggers: Gregory D. Pawelski on Genomics And Targets For The Treatment Of Cancer: Is Our New World Turning Into "Pharmageddon" Or Are We On The Threshold Of Great Discoveries?
Gregory D. Pawelski on Genomics And Targets For The Treatment Of Cancer: Is Our New World Turning Into "Pharmageddon" Or Are We On The Threshold Of Great Discoveries?
"I was telling your old colleague, Dr. Herman Kattlove, who posted about this on his blog, I thought his "genetic heterogeneity" terminology was more befitting than what was used in the title of the British study (Intratumor Heterogeneity). "Taking one biopsy sample of a tumor may not be enough to reveal its full genetic identity," was described by Medical News Today's Catharine Paddock, PhD. The study is significant because it suggests relying on one sample could overlook (other) important biomarkers that help make tailored treatments effective, explaining perhaps why personalized cancer therapy has been less successful than expected. Dr. Robert Nagourney, Medical and Laboratory Director at Rational Therapeutics, Inc., Long Beach, California, pointed out the disturbing news regarding the predictive validity and clinical applicability of human tumor genomic analysis for the selection of (targeted) chemotherapeutic agents. He also pointed out the accompanying editorial by Dr. Dan Longo, which made several points worth noting. First, he states that "DNA is not the whole story." This should be familiar to those who follow cell function analysis. Dr. Longo references Albert Einstein, who said, "Things should be made as simple as possible, but not simpler." Dr. Nagourney appreciates and applauds Dr. Long's comments for they echo his sentiments completely. The article of the study is only the most recent example of a growing litany of observations that call into question molecular biologist's preternatural fixation on genomic analyses. Human biology is not simple and malignantly transformed cells more are more complex still. Investigators who insist upon using genomic platforms to force disorderly cells into artificially ordered sub-categories, have once again been forced to admit that these oversimplifications fail to provide the needed insights for the advancement of cancer therapeutics. Those laboratories and corporations that offer "high price" genomic analyses for the selection of "high price" chemotherapy drugs take notice of this and related articles carefully as these reports portend a troubling future for their current business model ("personalized" cancer treatment)."
deadline April 18th: We’re Hiring: Web Development and Design Coordinator
We’re Hiring: Web Development and Design Coordinator
The Ovarian Cancer National Alliance is looking for a self-motivated individual with experience in web development, graphic design and web content management. The Web Development and Design Coordinator is responsible for designing and presenting content for the Alliance both online and in print. S/he manages online strategy development, maintains site standards, develops site promotions and works on online community and outreach campaigns.
This position reports to the Marketing and Communications Manager and supports the work of other departments, including Public Policy, Development and Events.
Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline [ASCO Special Articles]
Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline [ASCO Special Articles]:
pdf (open access)
Purpose
To provide recommendations for appropriate cytotoxic chemotherapy dosing for obese adult patients with cancer.
Methods
The American Society of Clinical Oncology convened a Panel of experts in medical and gynecologic oncology, clinical pharmacology, pharmacokinetics and pharmacogenetics, and biostatistics and a patient representative. MEDLINE searches identified studies published in English between 1996 and 2010, and a systematic review of the literature was conducted. A majority of studies involved breast, ovarian, colon, and lung cancers. This guideline does not address dosing for novel targeted agents.
Results
Practice pattern studies demonstrate that up to 40% of obese patients receive limited chemotherapy doses that are not based on actual body weight. Concerns about toxicity or overdosing in obese patients with cancer, based on the use of actual body weight, are unfounded.
Recommendations
The Panel recommends that full weight–based cytotoxic chemotherapy doses be used to treat obese patients with cancer, particularly when the goal of treatment is cure. There is no evidence that short- or long-term toxicity is increased among obese patients receiving full weight–based doses. Most data indicate that myelosuppression is the same or less pronounced among the obese than the non-obese who are administered full weight–based doses. Clinicians should respond to all treatment-related toxicities in obese patients in the same ways they do for non-obese patients. The use of fixed-dose chemotherapy is rarely justified, but the Panel does recommend fixed dosing for a few select agents. The Panel recommends further research into the role of pharmacokinetics and pharmacogenetics to guide appropriate dosing of obese patients with cancer.
Exact Sciences website: (re: dna stool testing) Clinical Trial for average at risk patients
Blogger's Note: there are no dates on some of the website's pages
Clinical Trial
DeeP-C (Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer)
Exact Sciences is conducting a pivotal trial for the company’s multi-marker molecular diagnostic screening test for the early detection of colorectal cancer. The multi-center DeeP-C study will generate data to support Exact Sciences’ planned PMA submission to the U.S. Food and Drug Administration (FDA). Exact Sciences is planning to have approximately 60 sites in the U.S. and Canada participate in the study. Those sites are expected to enroll more than 10,000 patients between the ages of 50 and 84 who are at average risk for colorectal cancer. For more information on the study please go to:
www.clinicaltrials.gov
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer (DeeP-C)
This study is currently recruiting participants.
Verified August 2011 by Exact Sciences Corporation
First Received on July 18, 2011.
Last Updated on March 30, 2012
History of Changes
(excluded from trial (high risk):
- Subject has a family history of:
- Familial adenomatous polyposis (also referred to as "FAP").
- Hereditary non-polyposis colorectal cancer syndrome (also referred to as "HNPCC" or "Lynch Syndrome").
The Exact CRC screening test is an investigational device and is not available for sale in the United States.
Clinical Oncology News - Stool DNA Test Promising for Colorectal Screening
Clinical Oncology News - Stool DNA Test Promising for Colorectal Screening
"Stool DNA testing is moving the colorectal cancer (CRC) screening field a step closer to eradicating the disease, according to David Ahlquist, MD, Department of Gastroenterology and Hepatology at Mayo Clinic, Rochester, Minn., who helped develop this approach and presented recent findings at the 2012 Gastrointestinal Cancers Symposium.
Stool DNA testing detects tumor-specific DNA alterations in cells that are continually being shed into the stool from precancerous and cancerous lesions. The test is now being developed by Exact Sciences, a molecular diagnostics company in Madison, Wis.
The broad application of stool DNA testing in longitudinal screening programs is to prevent CRC through high precancer detection. In an invited lecture, Dr. Ahlquist said this claim is “not too bold and not hyperbole.” New-generation stool DNA testing, he said, offers “extraordinarily” high detection rates for curable cancers and precancers that are likely to progress. The test detects lesions on both sides of the colon with equal accuracy and reveals flat or serrated polyps likely to be missed by both fecal occult blood test and colonoscopy.
The noninvasive DNA test involves no diet or medication restrictions, no bowel preparation and is done at home using a stool sample. “It is user-friendly, affordable and offers individuals unlimited access by mail,” he added............
new WIKI website: Cowbird · FAQ
Cowbird · FAQ
Why do you call it Cowbird?
We chose the name Cowbird to express the combined qualities of a cow and a bird.Cows are slow, steady, and grounded, while birds are fast, free, and full of joy.
Most of the Internet — including websites like Facebook and Twitter — are all bird and no cow, while more traditional formats like novels and operas are all cow and no bird.
Cowbird combines these two extremes to form a new kind of storytelling medium — mixing the slow, deeply rooted, contemplative idea of a cow with the fast, efficient, playful idea of a bird.
abstract: Role of the Msh2 gene (Lynch Syndrome) in genome maintenance and development in mouse fetuses.
Role of the Msh2 gene in genome maintenance and development in mouse fetuses
These results indicate that elevated mutation levels have little effect on the development of the fetus, even if a mutator phenotype appears at the organogenesis stage.
Abstract
In an attempt to evaluate the roles of the mismatch repair gene Msh2 in genome maintenance and in development during the fetal stage, spontaneous mutations and several developmental indices were studied in Msh2-deficient lacZ-transgenic mouse fetuses.
news: Increased risk of cardiovascular disease for relatives of cancer patients
Increased risk of cardiovascular disease for relatives of cancer patients
03 April 2012
Lund University
A current study shows that the risk for coronary heart
disease and stroke increases by almost thirty per cent in a person whose
partner has cancer. The cause is probably the negative stress to which
the cancer patient’s relative is exposed......
Subscribe to:
Posts
(
Atom
)
Posts
